Evidence map›Paper›PMID 21953124›Full record

ArticleTransgenic research2012

Human U6 promoter drives stronger shRNA activity than its schistosome orthologue in Schistosoma mansoni and human fibrosarcoma cells.

Raphaël Duvoisin, Mary A Ayuk, Gabriel Rinaldi, Sutas Suttiprapa, Victoria H Mann, Clarence M Lee, Nicola Harris, Paul J Brindley

Open access · greenAbstract readComparative Study
In one paragraph

Article in Transgenic research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Base editing ofeLife · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. New research tools for urogenital schistosomiasis.The Journal of infectious diseases · 2015
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. New frontiers in schistosoma genomics and transcriptomics.Journal of parasitology research · 2012
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Raphaël DuvoisinDepartment of Microbiology, Immunology & Tropical Medicine, The George Washington University Medical Center, Ross Hall 448, 2300 I Street NW, Washington, DC 20037, USA.
Mary A Ayuk
Gabriel Rinaldi
Sutas Suttiprapa
Victoria H Mann
Clarence M Lee
Nicola Harris
Paul J Brindley
George Washington University · USWashington University Medical Center · USHoward University · USSwiss Vaccine Research Institute · CH

Funding

Transduction of Schistosoma mansoni by pseudotyped retrovirusR01AI072773 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI BRINDLEY, PAUL J · 2007 to 2011
$2.5M
NIAID NIH HHS HHSN272201000005CNIAID NIH HHS HHSN272201000005INIAID NIH HHS R01 AI072773NIAID NIH HHS R01AI072773
6 · The paper itself

Abstract

Blood flukes or schistosomes are the causative agents of human schistosomiasis, one of the major neglected tropical diseases. Draft genome sequences have been reported for schistosomes, but functional genomics tools are needed to investigate the role and essentiality of the newly reported genes. Vector based RNA interference can contribute to functional genomics analysis for schistosomes. Using mRNA encoding reporter firefly luciferase as a model target, we compared the performance of a schistosome and a human promoter from the U6 gene in driving shRNA in human fibrosarcoma cells and in cultured schistosomes. Further, both a retroviral [Murine leukemia virus (MLV)] and plasmid (piggyBac, pXL-Bac II) vector were utilized. The schistosome U6 gene promoter was 270 bp in length, the human U6 gene promoter was 264 bp; they shared 41% identity. Following transduction of both HT1080 fibrosarcoma cells and schistosomules of Schistosoma mansoni with pseudotyped MLV virions, stronger knockdown of luciferase activity was seen with the virions encoding the human U6 promoter driven shRNA than the schistosome U6 promoter. A similar trend was seen after transfection of HT1080 cells and schistosomules with the pXL-Bac-II constructs-stronger knockdown of luciferase activity was seen with constructs encoding the human compared to schistosome U6 promoter. The findings indicate that a human U6 gene promoter drives stronger shRNA activity than its schistosome orthologue, not only in a human cancer cell line but also in larval schistosomes. This RNA polymerase III promoter represents a potentially valuable component for vector based RNA interference studies in schistosomes and related platyhelminth parasites.

Indexed as

Promoter Regions, GeneticAnimalsCell Line, TumorEnzyme ActivationFibrosarcomaGenes, HelminthGenes, ReporterGenetic VectorsHumansLeukemia Virus, MurineLuciferases, FireflyPlasmidsRibonucleoprotein, U4-U6 Small NuclearRNA InterferenceRNA, MessengerRNA, Small InterferingLuciferases, FireflyRibonucleoprotein, U4-U6 Small NuclearRNA, MessengerRNA, Small Interfering

Identifiers

PMID21953124
PMCPMC3271131
OpenAlexW2123382976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.